Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study)

JOURNAL OF INFECTION

W B SAUNDERS CO LTD

1. ANRS\MIE
2. Ministere de l'Enseignement Superieur, de la Recherche et de l'Innovation
3. Ministere desSolidarites et de la Sante